

98. (New) A cell characterized by producing the monoclonal antibody as claimed in claim 83.

99. (New) A hybridoma identified by an international deposit accession No. selected from the group consisting of FERM BP-6598, FERM BP-6599, FERM BP-6600, FERM BP-6208, FERM BP-6209 and FERM BP-6535.

100. (New) The antibody as claimed in claim 83, wherein the antibody is attached to a detectable label.

101. (New) The antibody as claimed in claim 100, wherein the label is selected from the group consisting of an enzyme, fluorescent substance, chemiluminescent substance, biotin, avidin, or radioisotope.

102. (New) A transgenic mouse in which DNA encoding human CTGF is integrated into an endogenous gene locus.

103. (New) An amino acid sequence of, or substantially equivalent to an amino acid sequence of SEQ ID NO: 2.

REMARKS

Claims 83-103 are now pending in this application and are supported in originally pending, now canceled claims 1-82.

Specific support can be found in the original claims as follows:

<u>New Claim</u>	<u>Original Claim(s)</u>
83	1
84	2
85	3
86	5
87	8
88	9

New Claim

Original Claim(s)

89	10
90	11
91	12
92	13
93	14, 15
94	17
95	18
96	19-26
97	20-26
98	32
99	36-40
100	45
101	46
102	59
103	60

No new matter has been added.

In the event any fees are due in connection with the filing of this preliminary amendment or attached application or if petitions are required, applicants petition for any required relief and authorize the Commissioner to charge the cost of such petitions or other fees to our Deposit Account No. 50-0815.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date:

June 23, 2000

By:

Karl Bozicevic
Karl Bozicevic
Registration No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\SHIM (SHIMIZU, FORMERLY SHI)\006\SHIM-006 US NAT'L PHASE PREAMEND.DOC